ArticleCureus2026
Seronegative Autoimmune Encephalitis With Neuropsychiatric Presentation: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seronegative autoimmune encephalitis (AE) is an immune-mediated inflammatory disorder of the central nervous system that presents with a broad spectrum of neuropsychiatric manifestations, including acute behavioral changes, cognitive dysfunction, catatonia, and altered levels of consciousness. The absence of identifiable neuronal autoantibodies in serum or cerebrospinal fluid contributes to diagnostic uncertainty, delayed treatment initiation, and increased morbidity. Given the potential reversibility of this condition, early recognition and prompt initiation of immunotherapy are critical to optimizing clinical outcomes. We report the case of a 68-year-old woman with probable seronegative AE who presented with subacute neuropsychiatric deterioration characterized by prominent psychiatric symptoms and catatonia. An extensive diagnostic evaluation, including cerebrospinal fluid analysis, comprehensive autoimmune antibody testing, and exclusion of infectious, metabolic, and structural etiologies, failed to identify an alternative diagnosis. Functional neuroimaging with 18F-fluorodeoxyglucose positron emission tomography revealed cerebral metabolic abnormalities supportive of an inflammatory encephalitic process. The patient demonstrated marked clinical improvement following early initiation of high-dose intravenous corticosteroid therapy. This case underscores the diagnostic complexity of seronegative AE when neuropsychiatric manifestations predominate and overlap with primary psychiatric disorders. It highlights the importance of maintaining a high index of clinical suspicion despite negative serological findings and supports the use of clinical diagnostic criteria and adjunctive functional neuroimaging to guide early immunotherapeutic intervention in suspected seronegative AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.